What Vagisan Treats: Main Uses and Benefits

The primary therapeutic use of Vagisan is generally applied in situations involving certain distressing symptoms, contributing to symptomatic support in areas where additional symptomatic support is needed. The therapeutic relevance of lactic acid in supporting the acidic environment is a recognized aspect of health literature.

This product is commonly used across conditions presenting with recurrent or episodic manifestations, including vaginal flora imbalances, non-specific irritation, and periods of heightened susceptibility to discomfort.

“This supportive therapy contributes to easing the overall symptom load and supports general well-being during symptomatic phases.”

Vagisan may assist with managing symptom clusters that may appear suddenly or fluctuate, such as vaginal burning, itching, generalized soreness, and pH-related malodorous discharge. It is applied across domains where short-term symptom management is appropriate, especially for those prone to relapse or post-antimicrobial use. Applied in scenarios where additional management of discomfort is required, it assists with maintaining functional stability.

---

Quick Fact: Supportive Assistance for Acute Discomfort Vagisan is generally applied in situations involving certain distressing symptoms, offering short-term symptomatic assistance to manage burning and itching symptoms related to inflammatory or irritative states.

The eligibility for using Vagisan Lactic Acid vaginal suppositories is defined by regulatory documents, which establish specific populations that are permitted, restricted, or strictly prohibited from use.

Eligibility Scope

Classification	Population/Condition	Regulatory Status
Absolute Contraindication	Known hypersensitivity to any ingredient (Lactic Acid, Macrogol, Sodium Lactate).	Must Not Be Used
Permitted Use	Adult women, Pregnant women, Breastfeeding women.	Allowed
Restricted Use	Girls/Children.	Consult Doctor First
Conditional Use	Current vaginal infection, Symptoms worsening/not improving within 8 days.	Consult Doctor First
Not Recommended	During menstrual periods.	Skip Treatment

Regulatory Eligibility Rules

The product is permitted for use in adult women, including those who are pregnant or breastfeeding. However, use is restricted in girls/children, who should only use the pessaries after consulting a doctor, as there is insufficient regulatory experience documented for this age group.

Use is formally contraindicated if the patient has a known allergy to any component of the suppository. Furthermore, the label advises against use during menstruation, and mandates a doctor's consultation for individuals experiencing an active vaginal infection or if symptoms do not improve within eight days of use. The eligibility profile is therefore defined by ingredient sensitivity and current physiological state.

Interactions with other medicines and products

Official regulatory documentation for Vagisan (Lactic Acid, Sodium Lactate) focuses on local interactions within the vaginal environment, rather than systemic drug-drug interactions, which is consistent with its localized action as a pH regulator. The interaction profile is primarily defined by a physical incompatibility warning and potential local pharmacodynamic effects.

Interaction-Related Restrictions

Interacting Entity	Interaction Classification	Official Restriction
Latex Contraceptives	Physical/Chemical Incompatibility	Restricted from simultaneous use.
Other Vaginal Products	Local Pharmacodynamic Effect	Caution advised for co-administration.

Co-administration with latex barrier contraceptives, such as condoms or diaphragms, is explicitly restricted. The product's suppository base, formulated with Macrogols, may potentially impair the tear resistance of the latex material, which could compromise the mechanical integrity and effectiveness of the contraceptive barrier.

Regarding other vaginal medicines, such as those used for treating infections, co-administration may temporarily alter the efficacy of Vagisan. Because the purpose of Vagisan is to establish and maintain an acidic pH environment, the simultaneous use of other preparations that significantly raise the local pH should be considered with caution, as this may counter the intended acidifying effect. No systemic pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters, are documented in official regulatory sources.

Physicochemical pH Modulation and Buffering

The primary mechanism of action involves the direct chemical modulation of the extracellular pH in the vaginal lumen. The Lactic Acid/Sodium Lactate buffer system immediately introduces hydrogen ions ( H^+) to drive the pH into the 3.8 to 4.4 range, while the buffer components stabilize this acidity, thereby modulating the local biochemical environment rather than targeting cellular receptors.

---

Selective Microbial Ecosystem Control

The resulting low pH establishes a selective growth environment. This acidity restricts the proliferation of most pH-sensitive, opportunistic microorganisms while favoring the proliferation and dominance of acid-tolerant Lactobacillus species. This mechanism modulates the local microbial ecology via environmental selection.

---

️ Reinforcement of the Acid Mantle Cascade

By facilitating the dominant population of native Lactobacillus through environmental control, the action initiates a self-reinforcing cascade. The increased activity of these bacteria leads to a sustained endogenous production of Lactic Acid, which supports the maintenance of the acid mantle.

How to Use Vagisan: Official Administration Guidelines

The usage of Vagisan Lactic Acid Pessaries is defined by specific official protocols regarding administration route, dosing, frequency, and duration. As an over-the-counter preparation, its use is governed by instructions designed to support the restoration and maintenance of the vaginal pH balance, a well-documented approach in supportive therapy.

---

Administration Scope

Instruction Domain	Official Labeled Protocol
Route of Administration	Vaginal (local, non-systemic administration)
Standard Dosing	One pessary per application
Time of Administration	Must be inserted in the evening before bedtime
Preparation	May be moistened under running water before insertion if the vagina is dry

---

Dosing Schedules and Duration

The administration schedule is officially structured to accommodate both acute and long-term use patterns. The standard regimen for an initial or acute course involves the use of one pessary once daily. The typical duration for this short-term regimen is a course of five to seven days. For continuous supportive use, the administration is typically changed to an intermittent, lower-frequency pattern of two to three times per week over a longer period.

Administration Constraints

Certain procedural constraints must be observed for proper use. The treatment course is not recommended during the menstrual period and should be suspended until the end of menstruation. Furthermore, use is advised against concurrently with latex condoms or diaphragms, as the product's components may potentially compromise the material's integrity. For specific populations, while the product is permitted for use during pregnancy and breastfeeding, administration to girls is limited and requires prior consultation with a physician.

Research Evidence / Overview of Studies for Vagisan

Evidence for Use in Vaginal pH and Flora Restoration

The primary research for this type of preparation focuses on its application in studies examining vaginal acidity. Studies, which include systematic reviews and randomized controlled trials (RCTs), examine the product's impact on vaginal pH levels—a key biological marker—and the environment for Lactobacillus species. Outcomes monitored included changes in the vaginal flora and tracking participants to see how often pH imbalances returned.

Findings describe patterns observed in the studies where use was associated with a shift toward a lower, more acidic vaginal pH in the short-term. Some trials suggested that the application of lactic acid preparations was examined in relation to the reported frequency of future flora imbalances. This evidence contributes to understanding symptom patterns related to mild discharge and irritation.

Evidence in Symptom Management for Post-Menopausal Women

Research has explored the use of lactic acid suppositories in observational settings for women experiencing symptoms related to vulvovaginal atrophy ( VVA) following menopause. These studies, which are often non-comparative trials, examine pH levels and patient-reported outcomes describing perceived discomfort, such as vaginal dryness and burning.

This evidence is generally classed as Low certainty. The majority of the studies were observed in non-randomized, open-label settings. This means that comparative evidence is lacking against placebo or established hormonal treatments. The follow-up durations were limited in most key studies, meaning long-term effects are not fully established for this chronic condition.

Evaluation of Lactic Acid in Acute Contexts and Research Gaps

RCTs have explored the use of lactic acid preparations in the context of acute bacterial vaginosis ( BV). The findings from these comparative trials were mixed. Some studies indicated that the preparation alone may not be as successful as standard antibiotic treatments for achieving a definitive clinical cure, though some subjective symptom scores were similar between the groups. The overall certainty remains low to moderate across the different uses explored. This is because comparative evidence is lacking against placebo or standard care in many areas, and the sample sizes were modest in numerous reported trials.

Key Studies & References

1. The Role of Lactic Acid in the Management of Bacterial Vaginosis: A Systematic Literature Review

Common questions about Vagisan (FAQ)

Q: Are there different types of Vagisan products for different issues?

A: Yes, official product information describes different primary types. For instance, Vagisan Lactic Acid products are intended for pH restoration to support the natural environment and help prevent recurrent infections. In contrast, Vagisan MoistCream products are designed for moisturizing to relieve the symptoms of vaginal dryness.

Q: How quickly can I expect to notice any effects from using Vagisan?

A: The Lactic Acid system works immediately to modulate the vaginal pH upon application. If local discomfort, such as burning or stinging, is experienced, official information indicates it is typically noted at the start of the treatment period and is generally transient.

Q: Is there a maximum amount of time Vagisan should be used?

A: Official usage patterns define a short-term regimen for acute use, typically lasting five to seven days. For continuous supportive use, the regimen is typically intermittent, such as two to three times per week, over a longer period. A formal regulatory maximum duration for this intermittent long-term use is not specified.

Q: Can Vagisan be used for general dryness, not just menopausal symptoms?

A: According to official product information, the moisturizing product, Vagisan MoistCream, is indicated for symptoms of dryness caused by oestrogen deficiency (e.g., during menopause). It is also indicated for dryness stemming from other causes, such as certain medications, stress, or metabolic disorders.

Q: Is Vagisan safe for people with sensitive skin or allergies?

A: The product is contraindicated (must not be used) in cases of known hypersensitivity to any of its components, which includes the active ingredients and excipients. The Lactic Acid pessaries are officially described as being free of fragrances, colourants, preservatives, and animal-derived substances.

Q: How does the action of Vagisan compare to estrogen creams?

A: Official information describes Vagisan as a hormone-free preparation that functions primarily as a pH regulator or moisturizer. This distinguishes its localized, non-systemic mechanism of action from that of hormonal therapies, with Vagisan potentially being used alongside or alternating with hormonal creams.

Q: How does Vagisan help with issues caused by low estrogen?

A: Symptoms linked to low oestrogen, such as reduced vaginal fluid and tissue fragility, are addressed by Vagisan products in a localized manner. The products work either by restoring the natural acidic pH balance or by providing moisturizing lipids to relieve the resultant discomfort and support tissue suppleness.

Q: Why might a doctor suggest Vagisan instead of other options?

A: The product's profile, as described in regulatory documents, is defined by its hormone-free status and its function as a pH regulator or moisturizer. Its profile describes its suitability for women who are unable to use or prefer not to use local oestrogen treatments for vaginal symptoms.

Q: Will Vagisan help with pain during intercourse?

A: The moisturizing formulation, Vagisan MoistCream, is officially indicated for symptoms of dryness which include pain during intercourse ( dyspareunia). The cream is also noted to be applied to facilitate sexual intercourse.

Q: What are the official sources of information for Vagisan's ingredients and safety?

A: The safety profile, ingredients, and regulatory classification are established by official sources. These include regulatory documentation from national drug agencies where the product is approved, such as the EMA / SmPC and TGA.

Q: What is the chemical name of the active component in Vagisan?

A: The active components are referred to by their common chemical names: Lactic Acid and Sodium Lactate. The UNII identifier for Lactic Acid in the DailyMed database is 33X04XA5AT.

Q: Is Vagisan the same thing as a yeast infection treatment?

A: The Vagisan Lactic Acid pessaries are primarily used for pH restoration to help prevent recurrent vaginal infections. Official information suggests that Lactic Acid products are not antibiotic treatments and work by modulating the pH balance, which is different from treatments designed to cure acute bacterial or fungal infections.

Q: What is the difference between Vagisan and general moisturizers?

A: Vagisan MoistCream is an acidic cream, formulated with a high water content and nourishing lipids, and is set at a specific pH of 4.5. This targeted pH value distinguishes its acidic profile from general moisturizing products that do not have a specific pH-regulating function.

Q: Does Vagisan stain clothing or underwear?

A: The high solubility of the pessaries in the vagina can cause an increased, watery discharge that may affect clothing. Official instructions recommend using a panty liner.

Q: Does Vagisan have a specific scent or smell?

A: According to official product information, the Vagisan Lactic Acid pessaries are described as being free of fragrances.

Q: Is Vagisan suitable for vegans?

A: The Vagisan Lactic Acid pessaries are officially described as being free of animal-derived substances in their formulation.

Q: Are there different strengths or dosages of Vagisan available?

A: Official regulatory labeling describes only one standard strength of the Vagisan Lactic Acid pessary formulation. This standard strength contains 167 mg Lactic Acid and 100 mg Sodium Lactate per pessary.

How to Store and Dispose of Vagisan

Official regulatory labeling dictates specific storage and disposal requirements to maintain the stability and integrity of Vagisan products. The required storage conditions differ slightly depending on the specific product form:

Item	Lactic Acid Pessaries (Suppositories)	MoistCream (Cream)
Maximum Temperature	Do not store above mathbf30^circC (86°F)	Do not store above mathbf25^circC (77°F)
Stability After Opening	Not Applicable	Shelf life of 6 months after opening
Container Rule	Do not use if the individual strip is damaged	Keep the tube tightly closed

All forms of Vagisan must be kept out of the sight and reach of children to prevent accidental use. If the product is unused or expired, it must not be discarded in household trash or down the toilet, but should instead be disposed of in accordance with local requirements for waste material.